The news about the EU commission’s approval of Tresiba was not a huge surprise, as the drug had already been recommended by the medicines committee CHMP under the EMA.
“But it is obviously positive news for Novo Nordisk. Now they have final approval in Europe and can commence the battle with Lantus, the best selling insulin drug in Europe and the rest of the world. It looks like they will have a favourable label, where some of the advantages over Lantus are highlighted. Among these are fewer hypoglycaemia incidents and more powerful and more flexible dosage,” analyst Søren Løntoft Hansen tells Medwatch.